ADVOCATE. CONNECT. INNOVATE.

Gold

XOMA (US) LLC

Organization Address
2910 Seventh Street
Berkeley, CA 94710-2700

Organization Phone
(510) 204-7200|(510) 204-7274

Website
www.xoma.com

Industry
Biotech and Pharmaceutical

Sector
Therapeutics

Organization Description

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. The Company’s expanding pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 629, a synthetic peptide compound derived from bactericidal/permeability-increasing protein. XOMA’s proprietary development pipeline is primarily funded by multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA’s technologies and experienced team have contributed to the success of marketed antibody products, including RAPTIVA ® (efalizumab) for chronic moderate to severe plaque psoriasis and LUCENT ® (ranibizumab injection) for wet age-related macular degeneration. The Company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA’s proprietary Human Engineering and bacterial cell expression (BCE) technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses. In addition to developing its own products, XOMA develops products for premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. Xoma has a fully integrated product development infrastructure, extending from pre-clinical science to product launch, and a team of 300 employees at its Berkeley location. For more information, please visit http://www.xoma.com.